Tu Van Dao

Researcher Profile 6/10

Hanoi Medical University · Medicine and Pharmacy

63 publications · 3,001 citations · h-index 13

Information

🏛️Affiliation: Hanoi Medical University
🔬Field: Medicine and Pharmacy
🆔ORCID: 0000-0001-6858-8347
✍️Profile incomplete — add information

An h-index of 13 places this researcher in Medicine and Pharmacy, within the top 10% of 6,619 profiles in this field in our directory.

Featured publications

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma1,495 citations
NEJM Evidence · 2022 · DOI

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.404 citations
Journal of Clinical Oncology · 2022 · DOI

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma329 citations
Annals of Oncology · 2024 · DOI

Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC142 citations
Journal of Hepatology · 2025 · DOI

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)54 citations
Journal of Clinical Oncology · 2022 · DOI

Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma41 citations
Journal of Hepatology · 2024 · DOI

Ubiquitin carboxyl-terminal esterase L1 (UCHL1) is associated with stem-like cancer cell functions in pediatric high-grade glioma35 citations
PLoS ONE · 2017 · DOI

Intensive quadratic programming approach for home energy management systems with power utility requirements26 citations
International Journal of Electrical Power & Energy Systems · 2019 · DOI

BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).26 citations
Journal of Clinical Oncology · 2022 · DOI

947MO Five-year overall survival (OS) and OS by tumour response measures from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)25 citations
Annals of Oncology · 2024 · DOI

About the field of Medicine and Pharmacy

6,619researchers 91,896publications 2,589,484citations 4.2average h-index

Common research topics in this field:

Mosquito-borne diseases and controlAntibiotic Resistance in BacteriaTuberculosis Research and EpidemiologyMalaria Research and ControlCOVID-19 and Mental HealthHIV/AIDS Research and Interventions

Institutions with the most researchers in this field: